Artielle Immunotherapeutics is a clinical stage, venture-backed company headquartered in Portland, OR. Artielle is developing a novel class of drugs termed Recombinant T-cell receptor Ligands, or ‘RTLs’ to treat a wide range of T-cell mediated inflammatory diseases. Target indications include the autoimmune diseases multiple sclerosis (MS), celiac disease, type 1 diabetes, rheumatoid arthritis and uveitis, among others. Artielle’s lead candidate is RTL1000 to treat MS. The company recently completed Phase 1 safety studies with RTL1000 in patients with MS. Data from this trial indicate that RTL1000 is safe and well-tolerated. Artielle’s platform technology is the subject of a worldwide exclusive license with Oregon Health & Science University that covers all classes of RTLs and all therapeutic applications. The platform is covered by several issued US and foreign patents as well as over 20 patent applications.
